Vor Biopharma Inc

Vor Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Vor Bio Doses First Patient in Global Phase 3 UPSTREAM SjD Registrational Trial of Telitacicept in Primary Sjögren’s Disease

Vor Bio Announces $75 Million Private Placement with TCGX

Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference

Vor Bio to Participate in the 44th Annual J.P. Morgan Healthcare Conference